Evidence map›Paper›PMID 12764115›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2003

Vasopressin differentially modulates non-NMDA receptors in vasopressin and oxytocin neurons in the supraoptic nucleus.

Michiru Hirasawa, Didier Mouginot, Michael G Kozoriz, Samuel B Kombian, Quentin J Pittman

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. The Effects ofIranian journal of pharmaceutical research : IJPR · 2018
    Article
  6. Article
  7. Regulation of Neuronal Activity in Hypothalamic Vasopressin Neurons.Interdisciplinary information sciences · 2015
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Kainate receptor-induced retrograde inhibition of glutamatergic transmission in vasopressin neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
  13. GABA is excitatory in adult vasopressinergic neuroendocrine cells.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
  14. Opposing actions of endothelin-1 on glutamatergic transmission onto vasopressin and oxytocin neurons in the supraoptic nucleus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010
    Article
  15. ATP-sensitive potassium channel-mediated lactate effect on orexin neurons: implications for brain energetics during arousal.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michiru HirasawaNeuroscience Research Group, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, T2N 4N1 Canada. hirasawa@ucalgary.ca
Didier Mouginot
Michael G Kozoriz
Samuel B Kombian
Quentin J Pittman
University of Calgary · CACentre hospitalier de l'Université Laval · CAKuwait University · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnocellular neurons of the supraoptic nucleus release the neuropeptides oxytocin and vasopressin from their dendrites to regulate their synaptic inputs. This study aims to determine the cellular mechanism by which vasopressin modulates excitatory synaptic transmission. Presumably by electroporation through perforated patch, we were able to successfully introduce biocytin into cells in which we performed an electrophysiological study. This method enabled us to determine that roughly half of the recorded neurons were immunoreactive to oxytocin-associated neurophysin and showed two characteristic features: an inward rectification and a sustained outward rectification. The remaining half showed a linear voltage-current relationship and was immunoreactive to vasopressin-associated neurophysin. Using these electrophysiological characteristics and post hoc immunohistochemistry to identify vasopressin or oxytocin neurons, we found that vasopressin decreased evoked EPSCs in vasopressin neurons while increasing EPSCs in oxytocin neurons. In both types of neurons, EPSC decay constants were not affected, indicating that desensitization of non-NMDA receptors did not underlie the EPSC amplitude change. In vasopressin neurons, both vasopressin and a V1a receptor agonist, F-180, decreased AMPA-induced currents, an effect blocked by a V1a receptor antagonist SR49059. In oxytocin neurons, AMPA-induced currents were facilitated by vasopressin, whereas F-180 had no effect. An oxytocin receptor antagonist blocked the facilitatory effect of vasopressin. Thus, we conclude that vasopressin inhibits EPSCs in vasopressin neurons via postsynaptic V1a receptors, whereas it facilitates EPSCs in oxytocin neurons through oxytocin receptors.

Indexed as

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidAnimalsArginine VasopressinDendritesExcitatory Amino Acid AgonistsExcitatory Postsynaptic PotentialsFeedback, PhysiologicalImmunohistochemistryIn Vitro TechniquesMaleNeuronsNeurophysinsOxytocinPatch-Clamp TechniquesPresynaptic TerminalsRatsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidArginine VasopressinExcitatory Amino Acid AgonistsNeurophysinsOxytocinReceptors, N-Methyl-D-AspartateReceptors, OxytocinReceptors, Vasopressin

Identifiers

PMID12764115
PMCPMC6741118
OpenAlexW1704281213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.